Scientists find cancer relapse mechanism

12 January 2009

Cancer Research UK, a charity funded by private donations, says Chinese researchers have found that cancerous cells can regenerate long after  normal ones have been irrevocably damaged by apoptosis.

Research published in the British Journal of Cancer by scientists at the  University of Hong Kong details studies in which human cervical, skin,  liver and breast cancer cells were treated with three distinct chemicals  that cause apoptosis- jasplakinolide, staurosporine and ethanol.

Once the cells had been treated beyond the point at which normal ones  would be unable to heal from the damage caused by the agents, they were  removed. However, the cancerous cells were able to regain their shape,  function and ability to divide. Only once the nucleus of the cancerous  cells had begun to disintegrate was apoptosis assured.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight